Immunome, Inc.
665 Stockton Drive
Suite 100
Exton
PA
19341
United States
52 articles with Immunome, Inc.
-
Immunome Reports Third Quarter 2022 Financial Results
11/14/2022
Immunome, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
11/7/2022
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
-
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
8/23/2022
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced the publication of a peer-reviewed article in Clinical & Translational Immunology characterizing B cell repertoires in tissue samples from patients with breast cancer.
-
Immunome Reports Second Quarter 2022 Financial Results
8/5/2022
Immunome, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Veru Inc. has announced the publication of positive Phase III results from its COVID-19 antiviral therapeutics that could lead to potential Emergency Use Authorization.
-
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
7/6/2022
Immunome, Inc. today announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing.
-
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
6/9/2022
Immunome, Inc. today announced the first patient has been enrolled in a clinical trial of IMM-BCP-01, a three-antibody cocktail for the treatment of SARS-CoV-2 (COVID-19). Topline data is expected in the second half of this year, which is an update from our prior guidance.
-
Immunome to Present at the Jefferies Healthcare Conference
6/2/2022
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, PhD, President and CEO of Immunome, will present at the Jefferies Healthcare Conference on Thursday, June 9, at 2:30 p.m. ET.
-
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
5/23/2022
Immunome, Inc. today announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine.
-
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
5/19/2022
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant.
-
Immunome Reports First Quarter 2022 Financial Results
5/12/2022
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
3/28/2022
Immunome, Inc. today reported financial results for the fourth quarter ended December 31, 2021 and provided a corporate update.
-
It was a busy week for clinical trial announcements. Here's a look.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19
3/11/2022
Immunome, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of SARS-CoV-2 (COVID-19).
-
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
2/8/2022
Immunome, Inc. (Nasdaq: IMNM), today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University1).
-
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
1/10/2022
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced an update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).
-
Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
12/7/2021
Immunome, Inc. today announced that members of management will participate in a fireside chat hosted by Cantor Fitzgerald Analyst Brian Cheng on Wednesday, December 8, 2021 at 1:00 p.m. ET.
-
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
12/1/2021
Immunome, Inc. announced today that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529).
-
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
11/29/2021
Immunome, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).